Ionis Pharmaceuticals, Inc. (IONS)
29.04
+1.73
(+6.33%)
USD |
NASDAQ |
Nov 13, 16:00
28.90
-0.14
(-0.48%)
After-Hours: 19:59
Ionis Pharmaceuticals Enterprise Value : 4.834B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 4.834B |
| November 11, 2026 | 5.004B |
| November 10, 2026 | 4.980B |
| November 09, 2026 | 5.448B |
| November 06, 2026 | 6.849B |
| November 05, 2026 | 6.746B |
| November 04, 2026 | 6.971B |
| November 03, 2026 | 7.015B |
| November 02, 2026 | 7.152B |
| October 30, 2026 | 7.531B |
| October 29, 2026 | 7.676B |
| October 28, 2026 | 7.761B |
| October 27, 2026 | 7.605B |
| October 26, 2026 | 7.515B |
| October 23, 2026 | 7.433B |
| October 22, 2026 | 7.596B |
| October 21, 2026 | 7.656B |
| October 20, 2026 | 7.844B |
| October 19, 2026 | 7.674B |
| October 16, 2026 | 7.435B |
| October 15, 2026 | 7.631B |
| October 14, 2026 | 7.395B |
| October 13, 2026 | 7.342B |
| October 12, 2026 | 7.556B |
| October 09, 2026 | 7.824B |
| Date | Value |
|---|---|
| October 08, 2026 | 7.495B |
| October 07, 2026 | 7.638B |
| October 06, 2026 | 7.611B |
| October 05, 2026 | 7.528B |
| October 02, 2026 | 7.535B |
| October 01, 2026 | 7.611B |
| September 30, 2026 | 7.719B |
| September 29, 2026 | 7.736B |
| September 28, 2026 | 7.683B |
| September 25, 2026 | 7.505B |
| September 24, 2026 | 7.391B |
| September 23, 2026 | 7.411B |
| September 22, 2026 | 7.712B |
| September 21, 2026 | 7.572B |
| September 18, 2026 | 7.495B |
| September 17, 2026 | 7.878B |
| September 16, 2026 | 7.562B |
| September 15, 2026 | 7.961B |
| September 14, 2026 | 8.655B |
| September 11, 2026 | 9.114B |
| September 10, 2026 | 9.352B |
| September 09, 2026 | 9.413B |
| September 08, 2026 | 9.528B |
| September 04, 2026 | 9.756B |
| September 03, 2026 | 9.763B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| BridgeBio Pharma, Inc. | 18.15B |
| Biogen, Inc. | 43.52B |
| Ultragenyx Pharmaceutical, Inc. | 2.577B |
| Krystal Biotech, Inc. | 8.154B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -109.97M |
| Revenue (Quarterly) | 242.72M |
| Total Expenses (Quarterly) | 352.69M |
| EPS Diluted (Quarterly) | -0.6617 |
| Gross Profit Margin (Quarterly) | 95.39% |
| Profit Margin (Quarterly) | -45.31% |
| Earnings Yield | -11.47% |
| Normalized Earnings Yield | -11.80 |